CS-1002 |
SHR-8068; CS-1002 |
Phase 3 Clinical |
Cstone Pharmaceuticals |
Solid tumours; Stomach Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Botensilimab |
AGEN-1181 |
Phase 3 Clinical |
Agenus Inc |
Colonic Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Esophageal adenocarcinoma; Colorectal Neoplasms; Prostatic Neoplasms; Microsatellite Instability; Solid tumours; Pancreatic Neoplasms; Neoplasms; Fibrolamellar hepatocellular carcinoma; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Liver Neoplasms |
Details
|
Gotistobart |
ONC-392; BNT316; BNT-316 |
Phase 3 Clinical |
Oncoimmune Inc |
Carcinoma, Adenoid Cystic; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Ovarian Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Pancreatic Neoplasms; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Anorectal disorders; Solid tumours; Head and Neck Neoplasms |
Details
|
Erfonrilimab |
KN046; KN-046 |
Phase 3 Clinical |
Jiangsu Alphamab Biopharmaceuticals Co Ltd |
Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Thymoma; Esophageal Squamous Cell Carcinoma; Lymphoma; Solid tumours; Thymus Neoplasms; Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms |
Details
|
Volrustomig |
MEDI-5752; MEDI5752 |
Phase 3 Clinical |
Medimmune Llc |
Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular |
Details
|
BCD-217 |
BCD-217 |
Phase 3 Clinical |
Biocad |
Melanoma |
Details
|
Ipilimumab biosimilar (Innovent Biologics) |
IBI-310 |
Phase 3 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Solid tumours; Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Colonic Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Microsatellite Instability; Colorectal Neoplasms; Bile Duct Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
Pembrolizumab/Quavonlimab |
MK-1308A |
Phase 3 Clinical |
Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co Ltd |
Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma |
Details
|
YH-001 |
YH-001 |
Phase 2 Clinical |
Eucure Pharmaceutical Technology (Beijing) Co Ltd |
Liver Neoplasms; Solid tumours; Alopecia Areata; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
SI-B003 |
SI-B003 |
Phase 2 Clinical |
|
Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma |
Details
|
BMS-986288 |
BMS-986288 |
Phase 2 Clinical |
Cytomx Therapeutics Inc |
Neoplasms |
Details
|
Evalstotug |
CAB-CTLA-4; BA-3071 |
Phase 2 Clinical |
Bioatla, Beigene Ltd |
Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular |
Details
|
Vudalimab |
XmAb-20717; XmAb-717; XmAb 717 |
Phase 2 Clinical |
Xencor Inc |
Thymoma; Adenocarcinoma, Clear Cell; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Endometrial Neoplasms; Microsatellite instability-high cancer; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Adenoma, Acidophil; Colonic Neoplasms; Mesothelioma; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant |
Details
|
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) |
|
Phase 2 Clinical |
Hualan Genetic Engineering Co Ltd |
Melanoma |
Details
|
Lorigerlimab |
MGD-019; AEX1344 |
Phase 2 Clinical |
Macrogenics Inc |
Solid tumours; Liver Neoplasms; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) |
|
Phase 2 Clinical |
Changhai Hospital Of Shanghai |
Pancreatic Neoplasms |
Details
|
RP-2 |
RP-2 |
Phase 2 Clinical |
Replimune Group Inc, Bristol-Myers Squibb Company |
Neoplasms; Colorectal Neoplasms |
Details
|
Abatacept (Orban Biotech) |
|
Phase 2 Clinical |
Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases |
Diabetes Mellitus, Type 1 |
Details
|
Quavonlimab |
MK-1308; AK-107 |
Phase 2 Clinical |
Zhongshan Akeso Biopharma Co Ltd, Merck Sharp & Dohme Corp |
Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung |
Details
|
Zalifrelimab |
AGEN-1884; RebmAb-600; UGN-301 |
Phase 2 Clinical |
4-Antibody, Ludwig Institute For Cancer Research |
Solid tumours; Carcinoma; Hemangiosarcoma; Urinary Bladder Neoplasms; Sarcoma; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung |
Details
|
BMS-986218 (Bristol-Myers Squibb) |
BMS-986218 |
Phase 2 Clinical |
Bristol-Myers Squibb Company |
Solid tumours; Liver Neoplasms; Adrenal Gland Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Lung Neoplasms |
Details
|
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Neoplasms |
Details
|
KD-6001 |
KD-6001 |
Phase 2 Clinical |
Shanghai Kanda Bio-Technology Co Ltd, Shanghai Celgen Bio-Pharmaceutical Co Ltd |
Liver Neoplasms; Solid tumours; Neoplasms; Melanoma; Carcinoma, Hepatocellular |
Details
|
BT-001 |
BT-001 |
Phase 2 Clinical |
Transgene Sa |
Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma |
Details
|
Porustobart |
HBM-4003; HCAb 4003-2 |
Phase 2 Clinical |
Harbour Biomed |
Solid tumours; Neoplasms; Neuroendocrine Tumors; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular |
Details
|
JK-08 |
JK-08 |
Phase 2 Clinical |
Xinlitai (Chengdu) Biological Technology Co Ltd |
Small Cell Lung Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Carcinoma, Squamous Cell; Thyroid Neoplasms; Colorectal Neoplasms; Carcinoma, Ovarian Epithelial; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms |
Details
|
Sovipostobart |
BMS-986249 |
Phase 2 Clinical |
Cytomx Therapeutics Inc |
Neoplasms |
Details
|
GI-101 |
SIM-323; SIM323; GI-101 |
Phase 2 Clinical |
GI Innovation Inc |
Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Vulvar Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis |
Details
|
Firastotug |
ADG-116 |
Phase 2 Clinical |
Adagene (Suzhou) Ltd |
Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
COYA-302 |
COYA302; COYA 302; COYA-302 |
Phase 2 Clinical |
Coya Therapeutics Inc |
Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis |
Details
|
GI-102 |
GI-102 |
Phase 2 Clinical |
GI Innovation Inc |
Solid tumours; Neoplasm Metastasis |
Details
|
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T |
|
Phase 2 Clinical |
Shanghai Cell Therapy Research Institute |
Solid tumours |
Details
|
XTX-101 |
XTX-101 |
Phase 2 Clinical |
Xilio Development Inc |
Solid tumours |
Details
|
RP-3 |
RP-3 |
Phase 2 Clinical |
Replimune Inc |
Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Hepatocellular |
Details
|
Muzastotug |
ADG-126 |
Phase 2 Clinical |
Adagene Inc |
Liver Neoplasms; Solid tumours; Neoplasms; Neoplasm Metastasis |
Details
|
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) |
|
Phase 2 Clinical |
Shanghai Zhongshan Hospital |
Cholangiocarcinoma |
Details
|
JS-007 |
JS007; JS-007 |
Phase 2 Clinical |
Shanghai Junshi Biosciences Co Ltd |
Solid tumours; Pancreatic Neoplasms; Neoplasms; Lung Neoplasms; Melanoma |
Details
|
KN-044 |
KN-044 |
Phase 1 Clinical |
Suzhou Alphamab Co Ltd |
Solid tumours |
Details
|
Bavunalimab |
XmAb-22841; XmAb-841 |
Phase 1 Clinical |
Xencor Inc |
Cholangiocarcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck |
Details
|
ATOR-1015 |
ADC-1015; ATOR-1015 |
Phase 1 Clinical |
Alligator Bioscience Ab |
Solid tumours; Neoplasms |
Details
|
Anti-CTLA-4 monoclonal antibody (Regeneron) |
REGN-4659 |
Phase 1 Clinical |
|
Carcinoma, Non-Small-Cell Lung |
Details
|
Ipilimumab biosimilar (Henlius) |
HLX13 |
Phase 1 Clinical |
Shanghai Henlius Biotech Inc |
Liver Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma |
Details
|
Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) |
MV-049 |
Phase 1 Clinical |
Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd |
Solid tumours |
Details
|
SAL-008 |
SAL-008 |
Phase 1 Clinical |
Xinlitai (Chengdu) Biological Technology Co Ltd |
Neoplasms |
Details
|
GIGA-564 |
GIGA-564 |
Phase 1 Clinical |
GigaGen Inc |
Solid tumours; Neoplasms |
Details
|
A-337 (Klus Pharma) |
A337 (Klus Pharma); A-337 (Klus Pharma) |
Phase 1 Clinical |
Klus Pharma Inc |
Neoplasms |
Details
|
BZE-2209 |
BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells |
Phase 1 Clinical |
Shanghai Cell Therapy Group Co Ltd |
Solid tumours |
Details
|
MT-8421 |
MT-8421; CTLA-4 ETB |
Phase 1 Clinical |
Molecular Templates Inc |
Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Mesothelioma; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular |
Details
|
STW204/Gotistobart |
AI-061 |
Phase 1 Clinical |
Oncoc4 Inc |
Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Digestive System Neoplasms; Urinary Bladder Neoplasms; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous |
Details
|
KM602 |
KM602; KM-602; XZP-KM602 |
Phase 1 Clinical |
Xuanzhu (Shijiazhuang) Biotechnology Co Ltd |
Solid tumours |
Details
|
TG-6050 |
TG-6050 |
Phase 1 Clinical |
Transgene Sa |
Carcinoma, Non-Small-Cell Lung |
Details
|
IMM-27M |
IMM27M; IMM-27M |
Phase 1 Clinical |
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd |
Solid tumours; Neoplasms; Pathologic Processes |
Details
|
TWP-102 |
TWP-102 |
Phase 1 Clinical |
Therawisdom Biopharma Co Ltd |
Neoplasms |
Details
|
SKB-337 |
SKB337; A-337; SKB-337 |
Phase 1 Clinical |
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd |
Solid tumours |
Details
|
CD-200-AR-L |
CD-200-AR-L; hP-1-A-8 |
Phase 1 Clinical |
University Of Minnesota, OX2 Therapeutics |
Glioblastoma; Glioma |
Details
|
BAT-4706 |
BAT-4706 |
Phase 1 Clinical |
Bio-Thera Solutions Ltd |
Solid tumours; Melanoma |
Details
|
FPT-155 |
CD80-Fc; FPT-155 |
Phase 1 Clinical |
Five Prime Therapeutics Inc |
Solid tumours |
Details
|
B7-2/GM-CSF cancer gene therapy |
CIT |
Phase 1 Clinical |
Radient |
Neoplasms |
Details
|